Reversion of Lipodystrophy after Switching from Protease Inhibitors to Non-nucleosides

The great enthusiasm with which protease inhibitors(PI) were received was curbed in the firstmonths of 1998 when body shape changes andlipid abnormalities were reported in subjects exposedfor a while to these drugs. In some cases,these mid, or long-term side effects were even associatedwith cardiovascular disease, includingcoronary ischemia. The rate of this lipodystrophysyndrome, as the illness is known, seems to increaseover time of exposure to PI, and is on average50% of in patients having being on PI for oneyear.